Cart
sales@molnova.com
PDE10-IN-1
CAS No. 1516896-09-5
PDE10-IN-1( —— )
Catalog No. M20167 CAS No. 1516896-09-5
PDE10-IN-1 is PDE10-IN-1 inhibitor extracted from Patent WO 2013192273 A1 for treating CNS and metabolic disorders.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 177 | In Stock |
|
| 5MG | 312 | In Stock |
|
| 10MG | 447 | In Stock |
|
| 25MG | 714 | In Stock |
|
| 50MG | 1017 | In Stock |
|
| 100MG | 1368 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePDE10-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionPDE10-IN-1 is PDE10-IN-1 inhibitor extracted from Patent WO 2013192273 A1 for treating CNS and metabolic disorders.
-
DescriptionPDE10-IN-1 is PDE10-IN-1 inhibitor extracted from Patent WO 2013192273 A1 for treating CNS and metabolic disorders.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetPDE
-
RecptorPDE10
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1516896-09-5
-
Formula Weight350.42
-
Molecular FormulaC23H18N4
-
Purity>98% (HPLC)
-
SolubilityDMSO:2 mg/mL?(5.41 mM)
-
SMILESCc1c(nc2c3cccnc3ccn12)[C@@H]1C[C@H]1c1nc2c(C)ncc(C)n2n1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Campbell John Emmerson et al. Preparation of heteroaryl compounds as PDE-10 inhibitors for treating CNS and metabolic disorders. Patent WO 2013192273 A1 20131227.
molnova catalog
related products
-
ATX inhibitor 5
ATX inhibitor 5 is a potent and orally active autotaxin (ATX) inhibitor (IC50: 15.3 nM) that reduces CCl4-induced hepatic fibrosis and exhibits anti-hepatic fibrosis effects.
-
Autotaxin-IN-3
Autotaxin-IN-3 is an Autotaxin(ATX) inhibitor (IC50: 2.4 nM) sourced from patent WO2018212534A1 (compound 33).
-
PDE10-IN-1
PDE10-IN-1 is PDE10-IN-1 inhibitor extracted from Patent WO 2013192273 A1 for treating CNS and metabolic disorders.
